Susana Carmona
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Susana Carmona has a total of 103 co-authors. Here are the top co-authors by number of shared publications:
- Conceição Egas
Biocant, Next Generation Unit, 3060-197 Cantanhede, Portugal
4 shared publications - Maria José Simões
Genoinseq, Next Generation Sequencing Unit, Biocant, Cantanhede, Portugal
4 shared publications A.I. Santos
Hospital Garcia de Orta, Almada, Portugal
2 shared publications- Ana Catarina Gomes
Hospital Garcia de Orta, Almada, Portugal
2 shared publications Andrew Singleton
Laboratory of Neurogenetics, National Institutes on Aging, NIH, Bethesda, MD, USA
2 shared publicationsCarlos Faro
2 shared publications
Latest Publications
- Open Access
- 1 March 2021
- Published by Elsevier in Revista Portuguesa de Cardiologia (English Edition)
- Vol. 40 (3) , 245.e1-245.e5
Exertional chest pain is sometimes more than just coronary atherosclerosis
- 1 March 2021
- Published by Elsevier in Revista Portuguesa de Cardiologia (English Edition)
- Vol. 40 (3) , 245.e1-245.e5
Open AccessExertional chest pain is sometimes more than just coronary atherosclerosis
- Open Access
- 1 March 2021
- Published by Elsevier in Revista Portuguesa de Cardiologia
- Vol. 40 (3) , 245.e1-245.e5
Exertional chest pain is sometimes more than just coronary atherosclerosis
- 1 March 2021
- Published by Elsevier in Revista Portuguesa de Cardiologia
- Vol. 40 (3) , 245.e1-245.e5
Open AccessExertional chest pain is sometimes more than just coronary atherosclerosis
- 1 March 2019
- Published by Elsevier in Neurobiology of Aging
- Vol. 75, 223.e1-223.e10
A comprehensive screening of copy number variability in dementia with Lewy bodies
- 1 March 2019
- Published by Elsevier in Neurobiology of Aging
- Vol. 75, 223.e1-223.e10
A comprehensive screening of copy number variability in dementia with Lewy bodies
- 1 October 2017
- Published by Elsevier in Neurobiology of Aging
- Vol. 58, 240.e1-240.e3
Mutations in TYROBP are not a common cause of dementia in a Turkish cohort
- 1 October 2017
- Published by Elsevier in Neurobiology of Aging
- Vol. 58, 240.e1-240.e3
Mutations in TYROBP are not a common cause of dementia in a Turkish cohort
- 21 April 2017
- Published by Wiley in American Journal of Medical Genetics Part A
- Vol. 173 (6) , 1607-1610
Novel de novo FOXC1 nonsense mutation in an Axenfeld‐Rieger syndrome patient
- 21 April 2017
- Published by Wiley in American Journal of Medical Genetics Part A
- Vol. 173 (6) , 1607-1610
Novel de novo FOXC1 nonsense mutation in an Axenfeld‐Rieger syndrome patient
- 7 June 2016
- Published by Taylor & Francis in Ophthalmic Genetics
- Vol. 38 (2) , 197-199
CYP1B1mutational screening in a Portuguese cohort of primary congenital glaucoma patients
Primary congenital glaucoma (PCG) is a rare and severe autosomal recessive disease, characterized by high intraocular pressure during the neonatal or early infantile period. If undetected and timel...
- 7 June 2016
- Published by Taylor & Francis in Ophthalmic Genetics
- Vol. 38 (2) , 197-199
CYP1B1mutational screening in a Portuguese cohort of primary congenital glaucoma patients
Primary congenital glaucoma (PCG) is a rare and severe autosomal recessive disease, characterized by high intraocular pressure during the neonatal or early infantile period. If undetected and timel...
- 10 October 2014
- Published by S. Karger AG in Ophthalmologica
- Vol. 232 (3) , 156-162
Genetic Variants in ICAM1, PPARGC1A and MTHFR Are Potentially Associated with Different Phenotypes of Diabetic Retinopathy
Purpose: To explore phenotype-genotype correlations that may contribute to a better understanding of diabetic retinopathy (DR). Procedures: An exploratory association study was performed to identify genetic variants associated with non-proliferative DR (NPDR) in 307 type 2 diabetic patients who were previously stratified into 3 different phenotypes of NPDR progression. The 307 patients were genotyped for 174 single nucleotide polymorphisms of 11 candidate genes (ACE, AGER, AKR1B1, ICAM1, MTHFR, NOS1, NOS3, PPARGC1A, TGFB1, TNF and VEGFA). Results: Significant associations were observed for PPARGC1A rs16874120 with phenotype A (odds ratio, OR = 0.60, 95% confidence interval, CI 0.36-0.99), ICAM1 rs1801714 with phenotype B (OR = 3.32, 95% CI 1.05-10.50) and both PPARGC1A rs10213440 (OR = 2.00, 95% CI 1.07-3.73) and MTHFR rs1801133 (OR = 1.84, 95% CI 1.08-3.11) with phenotype C. Conclusions: Results indicate that specific gene variants in ICAM1, PPARGC1A and MTHFR are associated with different NPDR phenotypes, being likely candidates to explain different disease mechanisms underlying the different phenotypes. This is the first study to show correlations between specific gene variants and NPDR phenotypes, opening new perspectives on DR.
- 10 October 2014
- Published by S. Karger AG in Ophthalmologica
- Vol. 232 (3) , 156-162
Genetic Variants in ICAM1, PPARGC1A and MTHFR Are Potentially Associated with Different Phenotypes of Diabetic Retinopathy
Purpose: To explore phenotype-genotype correlations that may contribute to a better understanding of diabetic retinopathy (DR). Procedures: An exploratory association study was performed to identify genetic variants associated with non-proliferative DR (NPDR) in 307 type 2 diabetic patients who were previously stratified into 3 different phenotypes of NPDR progression. The 307 patients were genotyped for 174 single nucleotide polymorphisms of 11 candidate genes (ACE, AGER, AKR1B1, ICAM1, MTHFR, NOS1, NOS3, PPARGC1A, TGFB1, TNF and VEGFA). Results: Significant associations were observed for PPARGC1A rs16874120 with phenotype A (odds ratio, OR = 0.60, 95% confidence interval, CI 0.36-0.99), ICAM1 rs1801714 with phenotype B (OR = 3.32, 95% CI 1.05-10.50) and both PPARGC1A rs10213440 (OR = 2.00, 95% CI 1.07-3.73) and MTHFR rs1801133 (OR = 1.84, 95% CI 1.08-3.11) with phenotype C. Conclusions: Results indicate that specific gene variants in ICAM1, PPARGC1A and MTHFR are associated with different NPDR phenotypes, being likely candidates to explain different disease mechanisms underlying the different phenotypes. This is the first study to show correlations between specific gene variants and NPDR phenotypes, opening new perspectives on DR.
- Open Access
- 13 October 2013
- Published by Wiley in Journal of Skin Cancer
- Vol. 2013, 1-4
Identification of DLEC1 D215N Somatic Mutation in Formalin Fixed Paraffin Embedded Melanoma and Melanocytic Nevi Specimens
DLEC1 has been suggested as a tumor suppressor gene in several cancers. DLEC1 D215N somatic mutation (COSM36702) was identified in a melanoma cell line through whole genome sequencing. However, little is known about the implication and prevalence of this mutation in primary melanomas or in melanocytic nevi. The aim of this study was to genotype DLEC1 D215N mutation in melanoma tissue and melanocytic nevi samples to confirm its occurrence and to estimate its prevalence. Primary melanomas () paired with synchronous or asynchronous metastases () from 81 melanoma patients and melanocytic nevi () were screened for DLEC1 D215N mutation. We found the mutation in 3 primary melanomas and in 2 melanocytic nevi, corresponding to a relatively low prevalence (3.7% and 7.1%, resp.). The pathogenic role of DLEC1 215N mutation is unclear. However, since the mutation has not been previously described in general population, its involvement in nevogenesis and melanoma progression remains a possibility to be clarified in future studies.- 13 October 2013
- Published by Wiley in Journal of Skin Cancer
- Vol. 2013, 1-4
Open AccessIdentification of DLEC1 D215N Somatic Mutation in Formalin Fixed Paraffin Embedded Melanoma and Melanocytic Nevi Specimens
DLEC1 has been suggested as a tumor suppressor gene in several cancers. DLEC1 D215N somatic mutation (COSM36702) was identified in a melanoma cell line through whole genome sequencing. However, little is known about the implication and prevalence of this mutation in primary melanomas or in melanocytic nevi. The aim of this study was to genotype DLEC1 D215N mutation in melanoma tissue and melanocytic nevi samples to confirm its occurrence and to estimate its prevalence. Primary melanomas () paired with synchronous or asynchronous metastases () from 81 melanoma patients and melanocytic nevi () were screened for DLEC1 D215N mutation. We found the mutation in 3 primary melanomas and in 2 melanocytic nevi, corresponding to a relatively low prevalence (3.7% and 7.1%, resp.). The pathogenic role of DLEC1 215N mutation is unclear. However, since the mutation has not been previously described in general population, its involvement in nevogenesis and melanoma progression remains a possibility to be clarified in future studies.